Telomir Pharmaceuticals, Inc. Common Stock
TELO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1 | $0 | $0 | $0 |
| G&A Expenses | $0 | $5 | $0 | $0 |
| SG&A Expenses | $0 | $5 | $2 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $5 | $2 | $3 |
| Operating Income | -$1 | -$5 | -$2 | -$3 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$1 | -$5 | -$2 | -$3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$5 | -$2 | -$3 |
| % Margin | – | – | – | – |
| EPS | -0.034 | -0.17 | -0.073 | -0.098 |
| % Growth | 80% | -132.2% | 25.3% | – |
| EPS Diluted | -0.034 | -0.17 | -0.073 | -0.098 |
| Weighted Avg Shares Out | 31 | 30 | 30 | 30 |
| Weighted Avg Shares Out Dil | 31 | 30 | 30 | 30 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$5 | -$2 | -$3 |
| % Margin | – | – | – | – |